News ArticleGlenmark Pharma Subsidiary IGI to Present Updated Clinical Data for ISB 2001 in Multiple Myeloma at ASH 2026
Phase 1 TRIgnite-1 study updates on first-in-class CD38 × BCMA × CD3 trispecific T-cell engager in heavily pretreated relapsed/refractory multiple myeloma patients
Glenmark Pharmaceuticals' subsidiary Ichnos Glenmark Innovation (IGI) will present updated Phase 1 clinical data of ISB 2001 (ABBV-2001), a first-in-class trispecific T-cell engager for relapsed/refractory multiple myeloma, at the 68th American Society of Hematology Annual Meeting, featuring longer follow-up data and initial dose-expansion results from heavily pretreated patients.
Glenmark Pharmaceuticals Limited
New Ventures
Glenmark Pharmaceuticals' clinical-stage biotechnology subsidiary, Ichnos Glenmark Innovation (IGI), announced it will present updated Phase 1 clinical data of ISB 2001 (ABBV-2001), an investigational trispecific T-cell engager targeting CD38, BCMA, and CD3, for relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting.
The updated data from the Phase 1 TRIgnite-1 study includes longer follow-up from the dose-escalation phase and early dose-expansion cohort results in heavily pretreated multiple myeloma patients.
ISB 2001 (ABBV-2001) is the first and only trispecific T-cell engager engineered to coordinate dual-antigen tumor recognition and T-cell engagement in a single molecule, developed using IGI’s BEAT® Multispecific Platform.
IGI, in collaboration with AbbVie under a global licensing agreement from July 2025, is advancing ISB 2001 through ongoing clinical studies including the TRIgnite-1 Phase 1 and a Phase 1/2 combination trial.
The oral presentation by Dr. Binod Dhakal is scheduled for December 12, 2026, at the ASH meeting in New Orleans, focusing on pharmacologic immunotherapies for multiple myeloma.
Highlights
- ISB 2001 (ABBV-2001) is a trispecific engager targeting CD38, BCMA on myeloma cells, and CD3 on T-cells.
- Phase 1 data shows robust efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma patients.
- Presentation at the 68th American Society of Hematology Annual Meeting on December 12, 2026.
- IGI collaborates globally with AbbVie for development and commercialization of ISB 2001.
- Updated clinical data includes longer follow-up from dose escalation and initial dose-expansion results.
Key Data Snapshot
What happened
- Ichnos Glenmark Innovation (IGI), Glenmark Pharmaceuticals’ biotechnology subsidiary, announced that updated clinical data for ISB 2001 (ABBV-2001) will be presented at the 68th ASH Annual Meeting.
- ISB 2001 is an investigational first- and only-in-class trispecific T-cell engager targeting CD38, BCMA, and CD3 for relapsed/refractory multiple myeloma (RRMM).
Key details
- Updated Phase 1 data includes longer follow-up from the dose-escalation phase and early results from dose-expansion cohorts in heavily pretreated multiple myeloma patients.
- The oral presentation will be by Dr. Binod Dhakal from the Medical College of Wisconsin on December 12, 2026.
- ISB 2001 is developed using IGI’s proprietary BEAT® technology platform, in collaboration with AbbVie under a global licensing agreement formed in July 2025.
Strategic context
- ISB 2001 is being evaluated as a potential new treatment for RRMM, addressing patients with limited therapeutic options.
- IGI is advancing a pipeline of novel Multispecific™ biologics aimed at hematologic cancers and solid tumors.
Regulatory and governance context
- This announcement was filed by Glenmark Pharmaceuticals on November 4, 2026, with BSE and NSE, under Scrip Code 532296.
- Presentation at a major scientific conference advances clinical validation and visibility of the ISB 2001 program.
Highlights
- ISB 2001 (ABBV-2001) is a trispecific engager targeting CD38, BCMA on myeloma cells, and CD3 on T-cells.
- Phase 1 data shows robust efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma patients.
- Presentation at the 68th American Society of Hematology Annual Meeting on December 12, 2026.
- IGI collaborates globally with AbbVie for development and commercialization of ISB 2001.
- Updated clinical data includes longer follow-up from dose escalation and initial dose-expansion results.
Disclosures
- Listing rules of BSE and NSE regarding timely disclosure
Source Information
More News on New Ventures
View allLatest corporate announcements and market updates in New Ventures.
Dr. Reddy's Secures Marketing Authorization for Generic Semaglutide Injection in Brazil for Type 2 Diabetes Treatment
Dr. Reddy's Laboratories announced it has received marketing authorization from Brazil's National Health Surveillance Agency (ANVISA) for its generic semaglutide injection, designed to treat adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Read Full Story
Power Finance Corporation Subsidiary Forms Siot Rajouri Akhnoor Transmission Ltd SPV for Jammu & Kashmir Transmission Project
Power Finance Corporation Limited's subsidiary, PFC Consulting Limited, has incorporated a wholly owned Special Purpose Vehicle (SPV) named Siot Rajouri Akhnoor Transmission Limited to develop a downstream transmission network from the 400/220 kV Grid Substation Siot in Rajouri, Jammu & Kashmir.
Read Full Story
Grasim and Suzlon Partner to Develop India's First Wind Turbines with Recyclable Blades Using Recyclamine® Technology
Grasim Industries Limited’s Advanced Materials Division and its subsidiary Aditya Birla Renewables Limited have signed a Memorandum of Understanding with Suzlon Energy Limited to develop and commercialize wind turbines featuring recyclable blades made with Recyclamine® technology, marking India’s first such initiative.
Read Full Story
